Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CSTLBullishIndustry Newsnews

High materiality7/10

Castle’s DecisionDx-Melanoma data support SLNB avoidance and targeted surveillance

Sep 30, 2026, 5:32 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive, clinically validated data improves test utility, may reduce invasive procedures, and can expand payer coverage and physician adoption, driving near-term revenue potential for CSTL.

AI summary

What happened, with direct paths to the underlying reporting

Castle Biosciences presents compelling EADV data for DecisionDx-Melanoma, showing low i31-SLNB risk with 4.4% SLN positivity and 99.6% 5-year RFS when SLNB is forgone in eligible patients. Transection analyses reinforce biology-driven risk, with 93.2% vs 64.1% 5-year RFS across classes, and high-risk results in early-stage disease approaching IIB risk, suggesting intensified follow-up. These findings could expand test adoption, reduce unnecessary procedures, and shape surveillance strategies, potentially improving outcomes and payer acceptance.

i31-SLNB low-risk results yield 4.4% SLN positivity; 5-year RFS 99.6% when SLNB avoided.
Transection data: 687 patients; 5-year RFS 93.2% (Class 1A) vs 64.1% (Class 2B).
Early-stage Class 2B RFS ~IIB; warrants closer surveillance and possible imaging.
Largest prospective, multicenter 2,799-patient GEP melanoma study across 29 U.S. centers.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.